Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05117996
Other study ID # RC21_123
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 5, 2022
Est. completion date July 2024

Study information

Verified date December 2022
Source Nantes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The European guidelines currently recommend to use 2 L of polyethylene glycol and free residue diet before any capsule endoscopy. However, up to now, no studies have been conducted to specifically evaluate bowel preparation modalities before small bowel capsule endoscopy in patients with Crohn's disease. In patients with Crohn's disease and small bowel ulcers, polyethylene glycol may remove some fibrin from these ulcers and alter bowel preparation. Moreover, it is important to select the most acceptable bowel preparation because patients with Crohn's disease will have to repeat capsule endoscopy several times after initiating treatment, for monitoring under treatment, or for detection of post-operative recurrence. In a preliminary retrospective study, it has been suggested that a simplified bowel preparation with liquid diet the evening before and water on the morning of the capsule endoscopy induced a better bowel preparation than the standard method with polyethylene glycol. Thus, the aim of the study is to demonstrate the superiority of this simplified bowel preparation compared to the standard preparation modality in terms of quality of bowel preparation, patient's acceptability and diagnostic yield.


Description:

Crohn's disease is a chronic inflammatory bowel disease characterized by the presence of ulcers that can affect the entire digestive tract, from the mouth to the anus. The existence of small bowel lesions is pejorative and associated with poorer outcomes and a higher risk of intestinal resection. Small bowel capsule endoscopy allows the visualization of the entire small bowel in a non-invasive and outpatient setting, without any anesthesia. It is the exam with the best diagnostic yield for the detection of small bowel ulcers in patients with Crohn's disease. Moreover, it allows the monitoring of patients after initiating treatment to assess mucosal healing and the detection of post-operative recurrence. As for any endoscopic examinations, its acceptability depends on bowel preparation modalities. The European Society of Gastrointestinal Endoscopy (ESGE) currently recommends to use 2 L of polyethylene glycol and free residue diet before any capsule endoscopy. However, patients with Crohn's disease were a minority (< 1.5 %) in the studies on which these guidelines are based on. Yet, in patients with small bowel Crohn's disease, polyethylene glycol may remove some fibrin from the ulcers and hence, alter bowel preparation. Moreover, it is important to select the most acceptable bowel preparation because patients with Crohn's disease will have to repeat capsule endoscopy several times after initiating treatment, for monitoring under treatment, or for detection of post-operative recurrence. A preliminary retrospective study suggested that a simplified bowel preparation with liquid diet the evening before and water on the morning of the capsule endoscopy induced a better bowel preparation than the standard method with polyethylene glycol. Thus, the aim of CROHN-PREP study is to demonstrate the superiority of this simplified bowel preparation compared to the standard preparation modality in terms of quality of bowel preparation, patient's acceptability and diagnostic yield.


Recruitment information / eligibility

Status Recruiting
Enrollment 144
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: - Patients of both genders aged over 18 years old - With an established diagnosis of Crohn's disease, whether active or quiescent - With an indication of a small bowel capsule endoscopy - Without any small bowel stricture (patency capsule procedure on the 7 days before the capsule endoscopy) - Registered with a social security scheme - Having provided their oral consent for the study after appropriate information Exclusion Criteria: - - Patients aged below 18 years old - Diagnosis of ulcerative colitis or IBD unclassified - Presence of an ileostomy - Presence of a small bowel syndrome - Symptoms suggestive of a small bowel stricture - Retention of the patency capsule on an abdominal X-ray performed 48 hours after the ingestion - Abdominal pain after the ingestion of the patency capsule - Planned abdominal surgery in the next month - Known intestinal fistula - Swallowing disorders - Established diagnosis of delayed gastric emptying or suggestive symptoms - Intake of non-steroidal anti-inflammatory drugs (NSAIDs) in the month prior to the capsule endoscopy - Intake of oral iron supplementation in the week prior to the capsule endoscopy - Intake of oral 5-ASA granules in the week prior to the capsule endoscopy - Ongoing pregnancy - Presence of a pace-maker or implantable defibrillator - Known allergy to polyethylene glycol or to lactose - Vulnerable people i.e. adults under a legal protection regime (guardianship, trusteeship, judicial safeguard)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
capsule endoscopy
capsule endoscopy
standard small bowel preparation
2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
Simplified small bowel preparation
Liquid diet the evening before and water on the morning of the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule

Locations

Country Name City State
France Angers University Hospital Angers
France Brest University hospital Brest
France Cholet hospital Cholet
France Vendée departmental hospital La Roche-sur-Yon
France Clinique Jules Verne Nantes
France Hopital privé Confluent Nantes
France Nantes University Hospital Nantes
France Rennes University hospital Rennes

Sponsors (1)

Lead Sponsor Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary KODA score (entire small bowel) Small bowel preparation quality (entire small bowel) through the reading of the capsule endoscopy, an average of 6 months
Secondary KODA score for each small bowel segment Small bowel preparation quality (by segment : upper/middle/lower third) through the reading of the capsule endoscopy, an average of 6 months
Secondary Qualitative assessment by the reader Proportion of images in which preparation is considered as "good", "moderate" or "low" by the reader (by segment) through the reading of the capsule endoscopy, an average of 6 months
Secondary Quantitative assessment of acceptability of preparation Patient's acceptability of the bowel preparation on a visual analog scale between 0 (nil) to 10 (excellent) Immediately before the capsule endoscopy
Secondary Quantitative assessment on a visual analog scale between 0 (nil) to 10 (excellent) Patient's acceptability of the examination on a visual analog scale between 0 (nil) to 10 (excellent) Immediately before the capsule endoscopy
Secondary Lewis score Diagnostic yield evaluation through the reading of the capsule endoscopy, an average of 6 months
Secondary complete examinations Percentage of complete examinations defined by the visualization of the first duodenal image and the first caecal image through the reading of the capsule endoscopy, an average of 6 months
Secondary Small bowel transit time Recording time between the visualization of the first duodenal image and the first caecal image, if visualized through the reading of the capsule endoscopy, an average of 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Recruiting NCT05169593 - Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy Phase 4
Recruiting NCT06116604 - Early Bowel Resection for Terminal Ileal Crohn's Disease
Recruiting NCT05627128 - A Culturally Tailored Dietary Intervention to Treat Crohn's Disease N/A
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT05294107 - Intestinal Organoids N/A
Not yet recruiting NCT05944068 - The Effects of a Mindfulness Based Intervention on IBD Disability N/A
Withdrawn NCT04349449 - ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT03058679 - Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease N/A
Completed NCT02871635 - BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity Phase 3
Recruiting NCT04266600 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease N/A
Recruiting NCT04539665 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease. N/A
Recruiting NCT03913572 - Treatment of Perianal Disease Using Adipose-derived Stem Cells
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed NCT03606499 - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Terminated NCT04102111 - A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease Phase 2
Recruiting NCT04997733 - Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal Phase 3
Not yet recruiting NCT04398836 - Preoperative Nutrition for Crohn's Disease Patients Phase 3
Not yet recruiting NCT04502303 - 18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease Phase 2